48 research outputs found
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
Non-small cell lung carcinoma remains by far the leading cause of cancer-related deaths worldwide. Overexpression of FLIP, which blocks the extrinsic apoptotic pathway by inhibiting caspase-8 activation, has been identified in various cancers. We investigated FLIP and procaspase-8 expression in NSCLC and the effect of HDAC inhibitors on FLIP expression, activation of caspase-8 and drug resistance in NSCLC and normal lung cell line models. Immunohistochemical analysis of cytoplasmic and nuclear FLIP and procaspase-8 protein expression was carried out using a novel digital pathology approach. Both FLIP and procaspase-8 were found to be significantly overexpressed in tumours, and importantly, high cytoplasmic expression of FLIP significantly correlated with shorter overall survival. Treatment with HDAC inhibitors targeting HDAC1-3 downregulated FLIP expression predominantly via post-transcriptional mechanisms, and this resulted in death receptor- and caspase-8-dependent apoptosis in NSCLC cells, but not normal lung cells. In addition, HDAC inhibitors synergized with TRAIL and cisplatin in NSCLC cells in a FLIP- and caspase-8-dependent manner. Thus, FLIP and procaspase-8 are overexpressed in NSCLC, and high cytoplasmic FLIP expression is indicative of poor prognosis. Targeting high FLIP expression using HDAC1-3 selective inhibitors such as entinostat to exploit high procaspase-8 expression in NSCLC has promising therapeutic potential, particularly when used in combination with TRAIL receptor-targeted agents
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors,
which have been classically viewed as intractable targets using small molecule inhibitor
approaches. Here, we demonstrate that AML driven by repressive transcription factors
including AML1-ETO and PML-RARα are extremely sensitive to Poly (ADP-ribose)
Polymerase (PARP) inhibitor (PARPi), in part due to their suppressed expression of key
homologous recombination genes and thus compromised DNA damage response (DDR).
In contrast, leukemia driven by MLL fusions with dominant transactivation ability is
proficient in DDR and insensitive to PARP inhibition. Intriguing, depletion of an MLL
downstream target, Hoxa9 that activates expression of various HR genes, impairs DDR
and sensitizes MLL leukemia to PARPi. Conversely, Hoxa9 over-expression confers
PARPi resistance to AML1-ETO and PML-RARα transformed cells. Together, these
studies describe a potential utility of PARPi-induced synthetic lethality for leukemia
treatment and reveal a novel molecular mechanism governing PARPi sensitivity in AML
Allogeneic stem cell transplantation for myelofibrosis in 2012.
Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF
Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT
Although CMML since long has been separated from MDS, many studies continue to evaluate the outcomes of both diseases after hematopoietic cell transplantation (allo-HCT) together. Data evaluating outcomes of a large CMML cohort after allo-HCT compared to MDS are limited. We aim to compare outcomes of CMML to MDS patients who underwent allo-HCT between 2010 and 2018. Patients ≥18 years with CMML and MDS undergoing allo-HCT reported to the EBMT registry were analyzed. Progression to AML before allo-HCT was an exclusion criterion. Overall survival (OS), progression/relapse-free survival (PFS), relapse incidence (including progression) (REL), and non-relapse mortality (NRM) were evaluated in univariable and multivariable (MVA) Cox proportional hazard models including interaction terms between disease and confounders. In total, 10832 patients who underwent allo-HCT were included in the study, there were a total of 1466 CMML, and 9366 MDS. The median age at time of allo-HCT in CMML (median 60.5, IQR 54.3–65.2 years) was significantly higher than in the MDS cohort (median 58.8, IQR 50.2–64.5 years; p < .001). A significantly higher percentage of CMML patients were male (69.4%) compared to MDS (61.2%; p < .001). There were no clinically meaningful differences in the distribution of Karnofsky score, Sorror HCT-CI score at allo-HCT, and donor type, between the CMML and MDS patients. RIC platforms were utilized in 63.9% of CMML allo-HCT, and in 61.4% of MDS patients (p = .08). In univariable analyses, we found that OS, PFS, and REL were significantly worse in CMML when compared with MDS (all p < .0001), whereas no significant difference was observed in NRM (p = .77). In multivariable analyses, the HR comparing MDS versus CMML for OS was 0.81 (95% CI, 0.74–0.88, p < .001), PFS 0.76 (95% CI 0.70–0.82, p < .001), relapse 0.66 (95% CI 0.59–0.74, p < .001), and NRM 0.87 (95% CI 0.78–0.98, p = .02), respectively. The association between baseline variables and outcome was found to be similar in MDS and CMML (all interaction p > .05) except for a decreasing trend over time of the risk of relapse in CMML (HR allo-HCT per year later 0.94, 95% CI 0.90–0.98), whereas no such trend was observed in MDS (HR 1.00, 95% CI 0.98–1.02). The poor outcome observed for CMML could be related to variables not measured in this study or to factors inherent to the disease itself. This study demonstrates that outcomes of CMML patients after allo-HCT are significantly worse compared to MDS. The results of this study may contribute to future recommendations for allo-HCT in CMML patients
Adoptive immunotherapy via Donor lymphocyte infusions following allogeneic haematopoietic stem cell transplantation for Myelofibrosis: A real world, retrospective multi-centre study
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for Myelofibrosis (MF). Relapse however remains a significant problem in up to 20-30% of cases. Donor Lymphocyte Infusions (DLI) represent a potentially effective strategy for relapse prevention and management, but optimal timing based on measurable residual disease (MRD)/chimerism analyses and regimen choice remain undetermined. We performed a retrospective ‘real world’ analysis of a multicentre cohort of MF allo-HCT patients from 8 European transplant centres who received DLI between 2005-2022. Response was assessed using IWG-MRT defined response criteria, and survival endpoints were estimated using the Kaplan-Meier estimator and log-rank test. The study included 28 patients with a median age of 58 years and a Karnofsky performance status of >80. The majority of patients had DIPPS-plus Intermediate-2 or high-risk disease at the time of allo-HCT. In vivo T cell depletion was utilised in 20 (71.2%) cases, with 19/20 patients receiving anti-thymocyte globulin (ATG). Indication for DLI was either ‘pre-emptive’ (n=15), due to a decrease in recipient chimerism (n=13) or molecular relapse (n=2), or ‘therapeutic’ (n=13) for clinician-defined haematological/ clinical relapse. No patient received DLI prophylactically. Median time to DLI administration was 23.4 months post allo-HCT. Of the 16 patients receiving >1 dose of DLI, 12 were part of a planned escalating dose regimen. Median follow-up from time of 1st DLI administration was 55.4 months. Response rates to DLI were CR (n=9), PR (n=1), and clinical improvement (n=6). Chimerism levels improved in 16 patients, and stable disease was reported in 5 patients. No response or progression was reported in 7 patients. DLI-induced aGVHD was reported in 11 (39%) cases, grade 3/4 (n=7;25%). Median overall survival from time of 1st DLI was 62.6 months, and the cumulative incidence of relapse/progression after 1st DLI was 30.8% at 6 months. This study highlights that good response rates can be achieved with DLI even after frank relapse in some patients within a cohort where other treatment options are very limited. More prospective studies are warranted to identify the optimal DLI regimen and timing to improve patient outcomes